PharmaCyte Biotech to Hold Shareholder Call
July 11 2016 - 9:00AM
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage
biotechnology company focused on developing targeted treatments for
cancer and diabetes using its signature live-cell encapsulation
technology, Cell-in-a-Box®, announced today that Chief Executive
Officer, Kenneth L. Waggoner, will conduct a shareholder conference
call at 4:30 p.m. EDT on Thursday, July 28, 2016.
Management will provide the latest information
to analysts and shareholders about PharmaCyte's clinical
development program and respond to questions. Analysts and
shareholders are requested to submit any questions they may have
about PharmaCyte’s clinical development program via email to
investorrelations@pharmacyte.com, Mr. Waggoner will respond to as
many of the questions as possible in the time permitted for the
call.
Date: |
July 28, 2016 |
Time: |
4:30 p.m. EDT |
Telephone Number: |
605.562.0020 |
Access Code: |
915-603-449 |
|
|
An audio replay will be available for two weeks.
PharmaCyte will provide a telephone number and access code to
listen to the recorded call the next day.
About PharmaCyte BiotechPharmaCyte Biotech is a
clinical stage biotechnology company developing and preparing to
commercialize treatments for cancer and diabetes based upon a
proprietary cellulose-based live cell encapsulation technology
known as “Cell-in-a-Box®.” This technology will be used as a
platform upon which treatments for several types of cancer and
diabetes are being developed. PharmaCyte’s treatment for cancer
involves encapsulating genetically modified live cells that convert
an inactive chemotherapy drug into its active or “cancer-killing”
form. These encapsulated live cells are placed as close to a
cancerous tumor as possible. Once implanted, a chemotherapy drug
that needs to be activated in the body (ifosfamide) is given
intravenously at one-third the normal dose. The ifosfamide is
carried by the circulatory system to where the encapsulated cells
have been placed. When the ifosfamide, which is normally activated
in the liver, comes in contact with the encapsulated live cells,
activation of the chemotherapy drug takes place at the source of
the cancer without any side effects from the chemotherapy. This
“targeted chemotherapy” has proven effective and safe in past
clinical trials.
In addition to developing a novel treatment for
cancer, PharmaCyte is developing a treatment for Type 1 diabetes
and insulin-dependent Type 2 diabetes. PharmaCyte plans to
encapsulate a human cell line that has been genetically engineered
to produce, store and release insulin in response to the levels of
blood sugar in the human body. The encapsulation will be done using
the Cell-in-a-Box® technology.
Safe Harbor This press release may contain
forward-looking statements regarding PharmaCyte Biotech and its
future events and results that involve inherent risks and
uncertainties. The words "anticipate", "believe", "estimate",
"expect", "intend", "plan" and similar expressions, as they relate
to PharmaCyte or its management, are intended to identify
forward-looking statements. Important factors, many of which are
beyond the control of PharmaCyte, could cause actual results to
differ materially from those set forth in the forward-looking
statements. They include PharmaCyte's ability to continue as a
going concern, delays or unsuccessful results in preclinical and
clinical trials, flaws or defects regarding its product candidates,
changes in relevant legislation or regulatory requirements,
uncertainty of protection of PharmaCyte’s intellectual property and
PharmaCyte’s continued ability to raise capital. PharmaCyte does
not assume any obligation to update any of these forward-looking
statements.
More information about PharmaCyte can be found
at www.PharmaCyte.com. It can also be obtained by contacting
Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com